- Good quality evidence on commonly used pain relief medication is limited.
- Undertake comprehensive assessment of pain, choosing appropriate analgesia commensurate with severity of pain (refer to Pain assessment guideline).
- Use lowest effective dose (reduced dosage and/or extended dose interval), titrate slowly and monitor for toxicity.
- Use transdermal and slow release opioids with caution, and only if liver function and pain control are stable.
- Ensure judicious management of bowels to minimise risk of constipation and encephalopathy.
Tables are best viewed in landscape mode on mobile devices
Drug |
Recommendations in liver disease |
Comment |
Paracetamol |
Consider standard dose 1g Consider dose reduction if In severe impairment use |
Avoid intravenous use |
NSAIDs |
Avoid use |
Interfere with platelet aggregation; prolong bleeding Increased risk of NSAID-induced renal impairment |
Codeine |
Avoid use |
Reduced/unpredictable analgesic effect |
Dihydrocodeine |
Avoid use |
Reduced/unpredictable analgesic effect |
QTTramadol |
Avoid if severe hepatic impairment |
Moderate hepatic impairment - increase Severe hepatic impairment – risk of lowering seizure threshold |
Morphine or |
Use with caution |
First-line strong opioid of choice Dose reduction may be necessary |
Oxycodone |
Use with caution |
Second-line strong opioid of choice Dose reduction may be necessary |
Hydromorphone |
Use with caution |
Dose reduction may be necessary |
Alfentanil |
Use with caution |
Dose reduction may be necessary |
Buprenorphine |
Use with caution |
Avoid transdermal products unless Use if transdermal product preferred and analgesic (refer to Buprenorphine information sheet) |
Fentanyl |
Use with caution |
Avoid transdermal products unless hepatic function and |
Tapentadol* |
Avoid if severe hepatic impairment Use with specialist |
Avoid use or reduce dose and extend dose interval |
QTMethadone |
Use with caution and seek |
Requires careful and very slow titration N.B: Complex pharmacokinetics means the accumulation |
QTPregabalin |
Not affected by hepatic impairment |
Caution due to potential for sedation |
Gabapentin |
Not affected by hepatic impairment |
Caution due to potential for sedation |
Avoid in severe liver failure |
Use with caution in mild to moderate hepatic impairment |
|
†Clonazepam |
No data |
Caution with moderate hepatic impairment Contra-indicated in severe hepatic impairment |
†Ketamine |
Use with caution and seek |
Dose reduction necessary. |
*Tapentadol as an immediate release tablet is not recommended by the Scottish Medicine Consortium (SMC), while the prolonged release tablets are accepted for restricted use for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics. This is restricted to use in patients in whom morphine sulphate modified release has failed to provide adequate pain control or is not tolerated. Refer to SMC guidance for prolonged release tablets and for immediate release tablets.